Sirona Biochem Announces Payment of Convertible Debenture Interests in Shares
October 20 2023 - 4:50PM
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF)
(“
Sirona” or the “
Company”)
announces that pursuant to the 12% unsecured, convertible
debentures in the principal amount of $1,500,000 (the
“
Debentures”) previously issued on April 20, 2023,
the Company will issue common shares in the capital of the Company
(the “
Common Shares”) in satisfaction of interest
payments on the outstanding Debentures (the “
Interest
Payments”).
The Company will issue an aggregate of
[1,380,979] Common Shares at
$[0.0675] [based on closing price of $0.09
on October 19, 2023 with 25% maximum discounted applied]
per Common Share to holders of the Debentures in satisfaction of an
aggregate of $[93,216] in interest payable as of
October 20, 2023.
Issuance of the Common Shares is subject to a
number of conditions, including receipt of all necessary corporate
and regulatory approvals, including the TSX Venture Exchange.
All securities issued in connection with the
Interest Payment will be subject to a statutory hold period of four
months plus a day from the date of issuance in accordance with
applicable securities legislation.
This news release does not constitute an offer
to sell or the solicitation of any offer to buy, nor shall there be
any sale of these securities in any jurisdiction in which such
offer, solicitation or sale would be unlawful. The Debentures and
the Shares which may be issued on exercise thereof have not been
and will not be registered under the United States Securities Act
of 1933, as amended (the “U.S. Securities Act”)
and may not be offered or sold in the United States absent
registration or an applicable exemption from the registration
requirements of the U.S. Securities Act and applicable state
securities laws.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug
discovery company with a proprietary platform technology. Sirona
specializes in stabilizing carbohydrate molecules with the goal of
improving efficacy and safety. New compounds are patented for
maximum revenue potential.
Sirona’s compounds are licensed to leading
companies around the world in return for licensing fees, milestone
fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is
in France and is the recipient of multiple French national
scientific awards and European Union and French government grants.
For more information, please visit www.sironabiochem.com.
For more information regarding this press
release, please contact:
Investor Enquiries:
Email: Info@sironabiochem.com
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward Looking Statements
This news release contains forward-looking
information, which involves known and unknown risks, uncertainties
and other factors that may cause actual events to differ materially
from current expectation. Important factors – including the
availability of funds and the results of financing efforts, – that
could cause actual results to differ materially from the Company’s
expectations are disclosed in the Company’s documents filed from
time to time on SEDAR (see www.sedarplus.ca). Readers are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date of this press release. The Company
disclaims any intention or obligation, except to the extent
required by law, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Uscf Sustainable Battery... (AMEX:ZSB)
Historical Stock Chart
From Jul 2024 to Aug 2024
Uscf Sustainable Battery... (AMEX:ZSB)
Historical Stock Chart
From Aug 2023 to Aug 2024